| 126.34 4.38 (3.59%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 172.99 |
1-year : | 202.05 |
| Resists | First : | 148.11 |
Second : | 172.99 |
| Pivot price | 120.01  |
|||
| Supports | First : | 118.05 |
Second : | 99.48 |
| MAs | MA(5) : | 121.72 |
MA(20) : | 125.11 |
| MA(100) : | 118.44 |
MA(250) : | 104.54 |
|
| MACD | MACD : | -2.2 |
Signal : | -2.5 |
| %K %D | K(14,3) : | 51.8 |
D(3) : | 47.4 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 148.11 | Low : | 73.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GKOS ] has closed below upper band by 37.5%. Bollinger Bands are 97.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 129.15 - 129.66 | 129.66 - 130.1 |
| Low: | 122.19 - 122.81 | 122.81 - 123.35 |
| Close: | 125.26 - 126.28 | 126.28 - 127.16 |
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Tue, 09 Jun 2026
A Look At Glaukos (GKOS) Valuation After Recent Share Price Swings - Yahoo Finance
Fri, 05 Jun 2026
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - TradingView
Thu, 04 Jun 2026
Glaukos Shareholders Reinforce Board, Pay and Auditor Support - The Globe and Mail
Wed, 03 Jun 2026
Glaukos (NYSE: GKOS) investors approve board slate, pay and Ernst & Young - Stock Titan
Mon, 25 May 2026
Glaukos Corporation (GKOS) Stock Analysis: Exploring a 28.5% Potential Upside with a Strong Buy Consensus - DirectorsTalk Interviews
Sun, 24 May 2026
Glaukos (GKOS) Valuation Check After Recent Share Price Pullback And Growth Narrative - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 59 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 102 (%) |
| Shares Short | 3,310 (K) |
| Shares Short P.Month | 3,230 (K) |
| EPS | -3.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.5 |
| Profit Margin | -34.4 % |
| Operating Margin | -13.2 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -26.4 % |
| Qtrly Rev. Growth | 41.2 % |
| Gross Profit (p.s.) | 7.33 |
| Sales Per Share | 9.38 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -38.29 |
| PEG Ratio | 0 |
| Price to Book value | 10.98 |
| Price to Sales | 13.45 |
| Price to Cash Flow | -844.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|